Lung cancer care is rapidly changing with advances in genomic testing, the development of next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations.
Introduction
A very exciting time exists in the field of thoracic malignancies. In the past year, we have witnessed tremendous advances in thoracic cancer research and treatment. In this annual report, now in its second year, we are pleased and excited to bring together leaders in the field to summarize recent major breakthroughs and significant advances in prevention and early detection, molecular diagnostics, pathology, staging, surgery, adjuvant therapy, radiotherapy (RT), molecular targeted therapy, and immunotherapy. Important progress has been made in SCLC and malignant mesothelioma and has also been included. With more novel treatment options, we reviewed the quality and value of such therapy, and lastly, a perspective on emerging trends and future directions in lung cancer research and treatment is provided.
Prevention and Early Detection
Cigarettes, E-cigarettes, and Cannabis Section Authors: Emily C. A. Stone, M.B.B.S., MMed, K. Michael Cummings, PhD, MPH, James R. Jett, MD Cigarettes. Tobacco cigarettes account for the vast majority of tobacco consumed worldwide and are by far the most lethal type of tobacco product consumed, costing global economies $1 trillion annually through loss of productivity and health care expenditure. 1 Tobacco control interventions such as higher taxes, graphic health warnings, mass media campaigns, and bans have led to a fall in smoking rates in developed countries, but less so in low-income countries where the tobacco industry is building market share. However, when such declines in smoking rates do occur, they result more from reduced youth uptake than from smoking cessation. Smokers are clearly looking for viable options to move away from cigarettes, but until recently few alternatives were available. The rapid uptake of e-cigarettes by smokers over the past decade has posed some interesting challenges for the medical profession. Will these new nicotine delivery products offer smokers an escape from cigarettes? Will nonsmokers (especially the young) be led into smoking? Another issue confronting the lung health field is the movement to legalize cannabis, which appears to be changing how cannabis is perceived and used, which in turn could have important health consequences in the future.
E-cigarettes. Electronic cigarettes (e-cigarettes) are a form of electronic nicotine delivery that has emerged as a potential alternative to conventional tobacco cigarettes and as a possible aid to tobacco cessation. A newly published systematic review identifies the need for frequent reevaluation of evidence in a field characterized by rapid change. 2 The regulatory status of the e-cigarette industry, an industry appropriated by global tobacco companies, varies around the world, with restrictions ranging from minimum age of purchase to a ban on sales altogether. 3 Although it does appear that e-cigarettes can help some smokers quit or reduce their smoking, the evidence is mixed. The recent U.S. surgeon general's report on e-cigarettes discourages the sale and use of any nicotinecontaining product by nonsmokers, especially the young. 4 Conversely, Public Health England cited e-cigarettes as "95% safer" than tobacco cigarettes, identifying their adoption by smokers as a key strategy for tobacco cessation. 5 A 2016 Cochrane review of e-cigarettes for smoking cessation identified two studies that showed an increased chance of smoking cessation with the use of nicotine e-cigarettes compared with nicotine-free e-cigarettes, but acknowledged a lack of evidence for long-term safety. 6 The likelihood of cigarette cessation was shown to be lower in those using e-cigarettes compared with other methods in a recent small study of patients with cancer. 7 A 2014 review of e-cigarettes in patients with lung cancer noted the urgency of smoking cessation after a diagnosis of lung cancer, but advised against recommending e-cigarette uptake after diagnosis, given the lack of safety and efficacy data. Cannabis is most commonly smoked but can be vaped, ingested, or used topically. Cannabinoids enter the bloodstream and reach the brain within seconds to a few minutes when smoked. Oral ingestion of cannabis takes 30 minutes or longer to have its effects in the brain.
The most recent and most comprehensive review of the health effects of cannabis use was recently published by the National Academies of Sciences, Engineering, and Medicine. 10 There is at least moderate evidence that cannabis is beneficial for chronic pain, neuropathic pain, and muscle spasms, especially related to multiple sclerosis. [11] [12] [13] [14] There is also moderate evidence that cannabis improves nausea and vomiting related to chemotherapy. There is less certain evidence that cannabis can increase appetite and prevent weight loss. 12, 15 Cannabis use has been found to impair driving ability, increase drowsiness, cause addiction in approximately 10% of users, and increase psychotic episodes and hyperemesis in heavy long-term users. 10, 15, 16 Cannabis smoke contains many of the same toxins as tobacco smoke, such as polycyclic aromatic hydrocarbons. Studies have shown that frequent cannabis use can cause chronic bronchitis (cough, sputum, and wheeze), but there is no established causality with chronic obstructive pulmonary disease. 17, 18 There is also no conclusive evidence that cannabis use increases the risk for lung cancer, although cannabis users often smoke cigarettes, making it difficult to isolate the impact of regular cannabis use on the risks for chronic lung disease. [19] [20] [21] The best evaluation of the association between smoking cannabis and lung cancer risk, after adjustment for tobacco use, is a pooled analysis of six case-control studies with 2159 patients with lung cancer and 2985 controls that failed to find evidence of an increased risk for lung cancer among longterm cannabis smokers. 20 Given the changing potency and patterns of use of cannabis, including use by non-cigarette smokers, there is an urgent need to conduct research to assess its effects on lung health.
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Lung Cancer Screening
Section Authors: John K. Field, PhD, FRCPath., Harry J. M. Groen, MD, PhD, James L. Mulshine, MD This is a very dynamic time for both computed tomography (CT)-based lung cancer screening research and the process of clinical implementation of routine CT lung cancer screening. Notable improvements in efficient screening detection rates have been reported, thus addressing concerns about high false positivity in screening work-ups. These reports, including the British pilot study UKLS, 22 the NELSON trial group study, 23,24 the I-ELCAP study, 25 and the preliminary experiences with the American College of Radiology LungRADS approach, 26, 27 cite false-positive diagnostic detection rates of less than 10%. In addition, the field recognized that nonstandardized terms for characterizing efficiency of the screening process were also confusing. Some investigators consider the finding of lung nodules on a CT scan as being equivalent to a cancer diagnosis, and because lung nodules are common in smokers, this misconception has resulted in the perception of a high false diagnosis rate. From a screening subject perspective, this situation leads to unnecessary distress; however, this situation in lung cancer screening could benefit from education for subjects and those involved in screening about the fact that pulmonary nodules are not equivalent to lung cancer, most pulmonary nodules are benign in origin, and lung cancer is a pathologic diagnosis rather than an imaging diagnosis. A consensus is emerging that working toward more systematic definitions for key parameters for a lung cancer screening is a near-term priority that could reset screening subjects's expectations and reduce anxiety regarding the process. 24, [28] [29] [30] [31] [32] [33] [34] [35] Additional areas of progress include a number of research efforts to effectively integrate tobacco cessation, both as a service and as a research focus, within the process of lung cancer screening. 36, 37 Dr. Jamie Ostroff of Memorial Sloan Kettering Institute is leading an exciting new research effort to address this vital aspect of lung cancer screening research.
A major Canadian effort buttressed the growing evidence on the cost-efficiency of providing high-quality lung cancer screening services while still providing a public health benefit. 38, 39 When conservative assumptions were used, an analysis of screening benefit was favorable relative to its impact on person-years of life saved. However, each nation has to make its own decision relative to the complex array of health priorities in each distinctive national setting.
Pathology and Staging
Pathology and Diagnostics
Section Authors: Yasushi Yatabe, MD, PhD, Lukas Bubendorf, MD, Sanja Dacic, MD, PhD
The acquisition of appropriate tumor material is crucial for accurate diagnosis and molecular testing of lung cancer. To meet the clinical demand, new methods have been developed. Electromagnetic navigation bronchoscopy using assisted CT allows precise targeting of peripheral nodules, 40 whereas transbronchial cryobiopsy is a promising tool to obtain large and high-quality specimens. 41 Several studies have reported that cytologic specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration or fine-needle aspiration are equally suitable for molecular testing. 42 The upcoming molecular testing guideline has been updated to include newer targetable genes (ROS1, rearranged during transfection proto-oncogene [ In addition to the traditional specimens, liquid biopsies (especially circulating tumor cell DNA [ctDNA]) have been increasingly used in clinical practice. Although the liquid biopsy has been investigated for use in relation to various targetable genes in NSCLC, it is mainly used in the detection of EGFR mutations when there is inadequate tumor sample or when the risk associated with biopsy is high. Although plasma EGFR testing has high specificity, the main concerns remain concordance with tissue biopsy results and its relatively low sensitivity, especially for T790M. This situation has improved with the use of advanced next-generation sequencing platforms. [44] [45] [46] [47] [48] [49] The U.S. Food and Drug Administration (FDA) has recently approved the cobas EGFR Mutation Test v2 plasma-based assay as a companion diagnostic for erlotinib. 50 If the plasma EGFR results are negative, tissue-based testing should be performed. 51 Saliva and urine have also been used to detect EGFR mutations.
Clinically, immune checkpoint inhibitors provide an additional treatment option in advanced NSCLC, and programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) is used as a biomarker to select patients who are more likely to respond to such treatment in either the first-or second-line setting. 52, 53 However, the development of different PD-L1 IHC assays with individual cutoff values, antibodies, and platforms for the immune checkpoint inhibitors has raised concerns among pathologists and oncologists (Table 1) . [54] [55] [56] To obtain some clarity, the five individual assays have been, and are currently being, compared with one another. [57] [58] [59] [60] [61] [62] Among these studies, first insights for possible harmonization of different PD-L1 IHC assays were provided with the BluePrint project, which was conducted in collaboration with pharmaceutical companies, diagnostic partners, the American Association for Cancer Research, and the IASLC. Three clones (22C3, 28-8, and SP263) showed similar results in tumor cell staining, whereas the SP142 assay displayed significantly less tumor cell staining. All assays stained immune cells with greater variability than tumor cells. 57 Recently, tumor mutation burden was focused on as an alternative predictive biomarker for immune checkpoint inhibitor treatment, as a high nonsynonymous mutational load is expected to lead to more tumor-specific T-cell responses though expression of neoantigens. 63 Indeed, the mutation burden enriched the patients who benefit from first-line therapy with nivolumab, and the combination of mutation burden plus high PD-L1 expression appeared to be more predictive. 64 
TNM Staging System
Section Author: Ramon Rami-Porta, MD, Frank C. Detterbeck, MD, Eric Lim, MBChB., MD, MSc
The eighth edition of the TNM classification of lung cancer [65] [66] [67] includes adenocarcinoma in situ (Tis[AIS]) and minimally invasive adenocarcinoma (T1mi) 68 ; incremental categories based on a 1-cm increase in tumor size from T1a-c to T2a-b, with tumors smaller than 5; 5 to no larger than 7 cm and those larger than 7 cm reclassified as T3 and T4, respectively; reclassification of endobronchial location less than 2 cm from the carina and total atelectasis-pneumonitis as T2; and diaphragmatic invasion as T4. 69 Nodal classification and intrathotracic metastasis remain unchanged. 70 Single extrathoracic metastasis is now classified as M1b separately from multiple extrathoracic metastases as M1c. 71 Amendments were made to stage grouping, 72 as well as to classification of lung cancers with multiple lesions. [73] [74] [75] [76] Overall survival (OS) by clinical stage according to the seventh and eigth editions is shown in Figure 1 .
The revised TNM classification for mesothelioma includes combination of T1a and T1b into the new T1 category, 77,78 collapse of N1 and N2 into the category N1, and reclassification of N3 as N2. 79 The M categories remain unchanged and stage grouping has been modified for improved stratification.
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The TNM classification of thymic epithelial malignancies was a joint effort of the IASLC and the International Thymic Malignancies Interest Group. 81 The T component is classified according to the involved organs. 82 Nodal involvement is divided into N1 (anterior [perithymic] nodes) and N2 (deep intrathoracic or supraclavicular nodes).
83,84 Stages I, II, IIIA, and IIIB are based on increasing local organ invasion, with stage IVA, including N1 and M1a (separate pleural or pericardial nodules) and stage IVB including N2 and M1b (intrapulmonary or distant organ metastasis). 85 For esophageal and esophagogastric junction cancers (cancers with their epicenter within the proximal 2 cm of the cardia), 86 tumors were staged clinically, 87 pathologically, 88 or pathologically after induction treatment. 89 This edition included subdivision of T4 into T4a and T4b depending on invaded organ; differentiation of clinical and pathologic stages for squamous and adenocarcinoma; introduction of pathologic stages after induction for both cancers; and introduction of prognostic subgroups based on anatomic extent, location, and differentiation grade.
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Therapy
Surgery
Section Authors: Hisao Asamura, MD, Jessica Donington, MD Minimally Invasive Lobectomy. Over the past 2 decades, video-assisted thoracic surgery (VATS) has become a common surgical technique. Along with it came improvements in operative and visual instruments. Although definition of VATS has been conflicting, VATS generally means operating by using thoracoscopy with a minimal number of small incisions and without rib spreading. Treatment of lung cancer by VATS has been performed under the assumption that it has an oncologic outcome equivalent to that of open thoracotomy but is a less invasive method. However, scientifically supported comparisons between VATS and open thoracotomy with randomized controlled trials have been scarcely reported. Some studies using large national or regional databases have reported that VATS had a lower incidence of postoperative complications or shorter length of hospital stay by 1 to 2 days, but there is uncertainty as to Figure 1 . Overall survival by clinical stage according to the seventh edition (A) and eighth edition (B) of the TNM staging system using the entire database available for the eighth edition. Survival is weighted by type of database submission: registry versus other. 72 MST, median survival time.
whether this is clinically meaningful. [93] [94] [95] [96] On the other hand, some reports concluded that a higher incidence of nodal upstaging has been observed in thoracotomy than in VATS, indicating the possibility of insufficient nodal evaluation in VATS. 97, 98 Of note, these conclusions were derived from retrospective studies; therefore, they always harbor hidden biases that may affect the outcome.
A randomized controlled trial from Denmark concluded that VATS was associated with less postoperative pain and better quality of life (QOL) compared with thoracotomy for the first year after surgery. 99 This study focused on the self-reported scoring systems of pain and QOL as outcomes. Further randomized studies that compare VATS to thoracotomy would be required to definitively demonstrate the prognostic equivalence and any differences in QOL or postoperative complications for these two surgical modalities.
Robot-assisted thoracic surgery (RATS) is defined as a surgical procedure that utilizes a robotic system for all or mostly all of the crucial aspects of the operation. In a recent retrospective study, RATS was reported to be equivalent to VATS in all measures of quality for treatment of lung cancer. 100 To date, no randomized trials have reported the comparative data between RATS and VATS/thoracotomy for lung cancer. 101 The extent of parenchymal resection remains an area of evolution. There are several situations where sublobar resection should be considered as primary treatment for early-stage NSCLC. In patients with limited pulmonary reserve or with poor physical conditions, sublobar resection, either as segmentectomy or wedge resection, can be reasonably selected as a surrogate for lobectomy. In cases of multiple primary NSCLCs, sublobar resections should be considered as well. Of course, there are anatomic limitations for such resection; however, there is no doubt that such surrogate resections could be selected.
Surgical Quality. The importance of surgical quality measures (QMs) in NSCLC was highlighted in 2016. Two independent studies from the National Cancer Database found that compliance with basic QMs was associated with improved OS after NSCLC resections. A study examining stage I NSCLC looked at (1) anatomic resection, (2) operation within 8 weeks of diagnosis, (3) R0 resection, and (4) more than 10 lymph nodes sampled. Whereas 99% of resections met at least one QM, only 22% satisfied all four. Median OS varied from 31 to 89 months for those who met no QMs as opposed to four QMs. 102 Similarly, in clinical stage IIIA, adherence to four QMs (neoadjuvant therapy, lobectomy or more extensive procedure, R0 resection, and >10 lymph nodes sampled) was examined and only 12.8% of stage IIIA resections satisfied all QMs. Median OS varied from 12 to 43.5 months for those who met no QMs compared with for those who met four. 103 Compliance with QMs was associated with age, insurance type, hospital volume, and comorbidity score but remained a strong independent predictor of survival in both studies. The benefit of thorough thoracic lymphadenectomy in early-stage NSCLC was further emphasized with multiple metaanalysis and population-based studies demonstrating improved OS when greater numbers of lymph nodes were resected and examined. [104] [105] [106] [107] [108] Adjuvant Therapy in Completely Resected NSCLC Section Authors: Heather Wakelee, MD, and Yi-Long Wu, MD Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II and IIIA NSCLC and is commonly used for patients with larger (at least 4 cm) stage IB tumors. In 2016 we learned from a subset analysis of the E1505 trial that the four platinumbased doublets utilized (cisplatin with either vinorelbine, gemcitabine, docetaxel, or pemetrexed) had comparable efficacy but differing toxicity profiles. 109 Further data to support the 4-cm cutoff to recommend adjuvant chemotherapy came from a propensity score-matched analysis performed in the Republic of Korea that divided stage IB patients into those with tumors 3 cm or smaller with visceral pleural invasion, tumors 3 to 4 cm in size, and tumors 4 to 5 cm in size. The study reported that the only group with a clear differential benefit from adjuvant chemotherapy was that with tumors 4 to 5 cm in size. 110 A Chinese study that utilized carboplatin/docetaxel and randomized nearly 200 patients to preoperative or postoperative therapy was presented at the IASLC World Conference on Lung Cancer 2016. 111 Both disease-free survival and OS trended in favor of the adjuvant approach, but the trial was too small to draw any definitive conclusions and leaves us with continued questions about the ideal strategy. Recent studies with strategies including the addition of bevacizumab in E1505 and the use of the MAGE-A3 vaccine in MAGRIT failed to demonstrate any improvement in survival with these approaches. 109, 112 Encouraging data from retrospective and nonrandomized trials of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant NSCLC have led to randomized trials, including the phase III RADIANT trial of adjuvant erlotinib or placebo. 113 In the EGFR-mutated subset (n ¼ 161) disease-free survival favored erlotinib (hazard ratio [HR] ¼ 0.61 [not significant]); OS did not trend favorably but was immature. marker. With approvals in advanced-stage disease, multiple programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors are now being studied in the adjuvant setting.
Advances in RT
Section Authors: Kristin Higgins, MD, Suresh Senan, MD Locally Advanced Stage III Disease. The standard of care for locally advanced NSCLC remains concurrent platinum-based chemotherapy and radiation to 60 to 66 Gy. 114 The PROCLAIM study evaluated two concurrent chemotherapy schemes, pemetrexed-cisplatin versus cisplatin-etoposide, with thoracic radiation therapy (TRT) in stage IIIA/IIIB nonsquamous NSCLC. Survival with pemetrexed-cisplatin-TRT was not superior, although grade 3 or lower neutropenia occurred less frequently in the pemetrexed arm. 115 A randomized study comparing intensity-modulated RT (IMRT) with passively scattered proton therapy reported no differences in the primary study end point of treatment failure (defined as either local progression or grade 3 or higher radiation pneumonitis). 116 Secondary analyses of the RTOG 0617 study found less high-grade pneumonitis, lower cardiac doses with use of IMRT versus threedimensional conformal radiation therapy, 117 and also less clinically meaningful decline in QOL with IMRT. 118 SBRT for Early-Stage and Oligometastatic Disease. The impact of stereotactic body RT (SBRT) for peripheral earlystage NSCLC is reflected in a Surveillance, Epidemiology, and End Results analysis showing that RT utilization rates for stage IA NSCLC increased from 13% to 29% between 2004 and 2012, with significant improvements in OS in the RT cohort. 119 A systematic review reported only limited changes in health-related QOL after SBRT. 120 For patients with centrally located lung tumors, both a prospective trial 121 and a literature overview 122 suggested that the toxicity rates of SBRT were acceptable, but the HILUS trial reported significant rates of fatal hemoptysis. 123 Mature data from prospective trials of SBRT for central tumors are awaited. In stage IV oligometastatic NSCLC (one to three metastatic lesions), a randomized phase II trial in patients not progressing after first-line systemic therapy demonstrated a significant improvement in progression-free survival (PFS) with local consolidative therapy (chemoradiotherapy or resection of all lesions) compared with standard therapy (11.9 months versus 3.9 months, log-rank p ¼ 0.0054). 124 Use of WBRT in NSCLC. Brain metastases will develop in up to 50% of patients with NSCLC. 125, 126 In selected patients, surgery or radiosurgery offers the best results.
However, patients with large-volume metastatic brain disease have traditionally been treated with whole brain RT (WBRT). In the QUARTZ trial, 538 patients with brain metastases from NSCLC who were ineligible for surgery or radiosurgery were randomized to WBRT (20 Gy in five fractions) or best supportive care. 127 The primary outcome measure was quality-adjusted life-years, and no differences in OS, QOL, or dexamethasone use were observed between the two groups. This study provides evidence that poor prognosis patients with brain metastases from NSCLC do not benefit from WBRT. However, the QUARTZ data are not applicable to younger patients, those with limited extracranial disease, and those for whom radiosurgery remains an option. New-Generation TKIs. Currently, ceritinib and alectinib are approved by the U.S. FDA as subsequent treatment options after crizotinib failure in ALK-positive patients. Several recent trials have provided clinical data on these drugs in the crizotinib-naive setting. In the ASCEND-4 study, which was a phase 3 study comparing ceritinib with chemotherapy, the median PFS was 16.6 months for ceritinib compared with 8.1 months for chemotherapy (HR ¼ 0.55, 95% confidence interval [CI]: 0.42-0.73, p < 0.00001). 128 The randomized phase 3 J-ALEX study compared alectinib, 300 mg twice daily, and crizotinib in Japanese patients without prior ALK inhibitor treatment. Alectinib was significantly superior to crizotinib, with PFS not reached versus 10.8 months, respectively (HR ¼ 0.34). 129 Results from a global phase 3 study (ALEX study) comparing alectinib, 600 mg twice daily, and crizotinib will likely be reported soon. Lorlatinib and brigatinib showed efficacy in patients with brain metastasis and/or resistant mutations, including G1202R. 130, 131 Phase 3 trials comparing these agents with crizotinib are ongoing.
ALK Resistance and Sequencing of Therapies. Resistance to first-and second-generation ALK TKIs may occur through ALK-dependent mechanisms (primarily ALK kinase secondary mutations or amplification) or ALK-independent mechanisms, including activation of oncogenic bypass tracts or cell lineage change (small cell or epithelial-to-mesenchymal transformations). 132, 133 Recently, Gainor et al. extensively characterized mutations in post-TKI biopsy specimens and identified differences in the frequency and type of secondary mutations occurring in patients progressing while receiving crizotinib compared with second-generation ALK TKIs. 134 Secondary ALK mutations were present in 20% to 30% of patients progressing while taking crizotinib compared with in more than 50% of patients progressing during treatment with a second-generation ALK TKI. Mutations such as L1196M and G1269A were frequent in post-crizotinib treatment biopsy specimens; they were less common after treatment with secondgeneration ALK TKIs. In contrast, G1202R, which was found in only 2% of post-crizotinib treatment specimens, was the most frequent mutation after treatment with second-generation TKIs. Interestingly, the mutation profile of tumors changes with time and with the influence of sequential ALK TKIs. 134, 135 Although the empirical use of sequential ALK TKIs such as crizotinib followed by ceritinib or alectinib has resulted in longterm disease control and excellent survival, characterization of resistance mechanisms by using serial tumor biopsy specimens has potential to guide selection of multiple, sequential lines of ALK inhibitor therapy. 136, 137 For example, the I1171 mutation that is associated with resistance to crizotinib and alectinib may be sensitive to ceritinib; alternatively, the G1202R mutation that is associated with resistance to crizotinib, alectinib, and ceritinib may be sensitive to the third-generation ALK TKI lorlatinib. The optimal treatment for patients with EGFR mutations continued to be refined in 2016. Key research findings centered around comparing first-line EGFR TKIs, solidifying the role of the newly approved osimertinib for acquired resistance, developing novel EGFR TKIs, and using plasma to genotype EGFR.
The LUX-Lung 7 trial compared first-line afatinib to geftinib among patients with EGFR mutation. A slight PFS benefit for afatinib (HR ¼ 0.73, 95% CI: 0.57-0.95, p ¼ 0.017) was seen, but the median PFS was 11 months in both arms. 138 Furthermore the OS was similar in both treatment arms, including analyses within exon 19 deletion and L858R. 139 At this time, whether there are clear differences between the first-line EGFR TKIs is unclear; therefore, afatinib, erlotinib, and gefitinib are all reasonable options.
In November 2015, osimertinib became the first U.S. FDA-approved T790M mutant-specific, wild-typesparing (third-generation) EGFR TKI. This year we saw mature results from two large single-arm phase II studies of osimertinib, 80 mg daily, in patients with T790M-mediated acquired resistance. The AURA extension and AURA2 trials showed overall response rates (ORRs) of 62% and 58%, disease control rates (DCRs) of 90% and 92%, and PFS times of 12.3 and 9.9 months, respectively. 140, 141 The phase III AURA3 trial randomized 419 EGFR-mutant patients with T790M after failure of first-line EGFR TKIs to osimertinib or platinum/pemetrexed; the PFS times were 10.1 and 4.4 months, respectively (HR ¼ 0.30, 95% CI: 0.23-0.41, p < 0.001).
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Osimertinib may also have unique central nervous system activity. 143 EGFR-mutant patients (EGFR T790M not required) with leptomeningeal disease were treated with osimertinib, 160 mg (BLOOM study). 144 Nine of 20 patients had radiographic responses; improvements in neurologic examination findings and declining levels of ctDNA in the cerebrospinal fluid were also reported. Promising PFS was seen with first-line osimertinib in patients with EGFR-mutant NSCLC, 145 and the results of a phase III study comparing osimertinib to erlotinib/ gefitinib (FLAURA) are greatly anticipated.
The need for tissue rebiopsy to determine T790M status can be a barrier to appropriate treatment selection. Plasma detection and semiquantitation of the activating EGFR and T790M mutation is a useful tool to predict the efficacy of osimertinib, 146 and an assay for T790M in ctDNA was U.S. FDA-approved in 2016 as a companion diagnostic to osimertinib. Novel techniques for T790M detection in both plasma and urine have been studied, 147 and minimally invasive assays are expected to gain prominence in the future.
Updates regarding several other novel EGFR TKIs were published in 2016. 148 Olmutinib was approved in the Republic of Korea, but global development has been halted. EGF816 149 and ASP8273 150 are active in T790M-positive patients. Rociletinib development has ceased owing to low activity in T790M-positive patients. 151, 152 A novel EGFR TKI, AZD3759, has increased central nervous system penetration but does not inhibit T790M. 153, 154 Finally, although immune therapy checkpoint inhibitors have had a huge impact in advanced NSCLC in 2016, the studies to date show little if any benefit for EGFR mutation-positive patients.
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ROS1
Section Authors: Alice Shaw, MD, PhD, Myung-Ju Ahn, MD, PhD
Resistance to crizotinib develops in almost all patients with ROS1-rearranged NSCLC. Although the mechanisms of acquired resistance are incompletely understood, several case series of repeat biopsies with supporting preclinical studies have identified missense mutations within the ROS1 kinase domain, such as G2032R, 158 D2033N, 159 S1986Y/F, 160 and L2155S, 161 which can mediate crizotinib resistance. The ROS1 G2032R mutation, which is located at the solvent front of the kinase hinge, confers high-level resistance to crizotinib and appears to be the most common resistance mechanism in crizotinib-treated patients. 162 Preclinical studies suggest that cabozantinib, 163 foretinib, 164 and lorlatinib 165 may be able to overcome this resistance mutation. The ROS1 D2033N resistance mutation was identified in a patient with CD74 molecule gene (CD74)-ROS1 fusion who relapsed while taking crizotinib. Like G2032R, D2033N is located at the solvent front of the kinase hinge. Notably, this patient was highly responsive to the multitargeted inhibitor cabozantinib, experiencing a rapid and durable clinical response. 159 Recently, a dual ROS1 kinase domain mutation, S1986Y and S1986F, was discovered in a ROS1-positive patient who had relapsed while receiving crizotinib. This patient subsequently responded to lorlatinib. 160 Finally, the novel resistance mutation, L2155S, was identified in crizotinib-resistant HCC78 cell lines harboring the solute carrier family 34 member 2 gene (SLC34A2)-ROS1 fusion. 161 Whether this ROS1 mutation will emerge in patients exposed to crizotinib remains to be determined. To date, the lorlatinib phase 1/2 trial represents the largest study to examine patients with crizotinib-resistant, ROS1-positive NSCLC. Preliminary data suggest that lorlatinib can induce responses in some patients, but ROS1 mutation status in these responders has not been reported. 130 A newer nextgeneration ROS1 inhibitor, TPX-0005, will soon enter phase 1 clinical testing. TPX-0005 has been specifically designed to overcome the solvent front mutations in ALK and ROS1, including ROS1 G2032R. 166 In addition to secondary mutations within ROS1, several different offtarget mechanisms of resistance have also been reported in crizotinib-resistant tumors, including a KIT proto-oncogene receptor tyrosine kinase gene (KIT) D816G activating mutation 167 and EGFR pathway activation. 168 Further studies of crizotinib-resistant tumor specimens are needed to fully define the spectrum of on-target and off-target resistance mechanisms in ROS1-positive NSCLC. Elucidating these mechanisms may inform the rational development of new treatment strategies for crizotinib-resistant, ROS1-positive NSCLC.
Other Targets
Section Authors: Daniel B. Costa, MD, PhD, Jyoti D.
Patel, MD
Although in 2016 approval of TKIs matched to a driver was restricted to tumors with genomic aberrations in EGFR, ALK and ROS1, [169] [170] [171] [172] [173] [174] [175] other putative driver events could predict for response to targeted therapies in advanced NSCLC, particularly in lung adenocarcinoma (Table 3 176-189 ). The genotype/inhibitor duo closest to receiving approval by the U.S. FDA and other worldwide regulatory agencies is the BRAF V600E mutation (found in w1% to 2% of adenocarcinomas) with dabrafenib plus trametinib, as the ORR of this BRAF plus MEK inhibitor combination is higher than 60% and is associated with prolonged disease control. [176] [177] [178] 190 The European Union approved the aforementioned combination in April 2017 and the FDA in June 2017.
Another promising treatable target is MET protooncogene receptor tyrosine kinase, which is also known as hepatocyte growth factor receptor. MET can be activated as a primary oncogenic driver in NSCLC by two independent mechanisms: high-level MET gene amplification (in w1% of adenocarcinomas) and MET exon 14 alterations (in w3%-4% of adenocarcinomas and >10% of sarcomatoid carcinomas). [191] [192] [193] [194] [195] [196] [197] Crizotinib, the U.S. FDA-approved ALK/ROS1/MET TKI, induces responses in close to half of patients with advanced cancers with MET alterations, 179, 180, 198 and there are ongoing clinical trials of multiple other multitargeted MET TKIs (see Table 3 ).
The activity of TKI monotherapy in other subgroups of lung cancer is less clear. 199, 200 The oncogene rearranged during transfection (RET) is seen in approximately 1% to 2% of patients with NSCLC; however, the ORR is less than 30% with the currently available multitargeted RET TKIs. [181] [182] [183] [184] 201, 202 ErbB2 receptor tyrosine kinase 2 (ERBB2 or HER2) exon 20 mutations occur in approximately 2% of lung adenocarcinomas. Currently available ERBB TKIs and monoclonal antibodies are minimally active and seldom reach an ORR higher than 20%. [186] [187] [188] 203, 204 More specific TKIs and rational combination approaches 185 may hold the promise of eventually leading to regulatory approval of precision therapies in these tumors (see Table 3 ). The drug development platform for driver oncogenes with a prevalence less than 1% in lung cancer, such as neurotrophic receptor tyrosine kinase (NTRK) or fibroblast growth factor receptor (FGFR) rearrangements, 189, [205] [206] [207] is more challenging (see Table 3 ) and may require large umbrella or basket trials that capture different molecular subgroups of lung cancer, such as Lung-MAP (NCT02154490) and the U.K. National Lung Matrix (NCT02664935), or that involve multiple cancer primaries binned by molecular alterations, such as NCI-MATCH (NCT02465060). 208 
Immunotherapy
Section Authors: Leora Horn, MD, MSc, Scott Gettinger, MD, Solange Peters, MD, PhD
In 2016 the first anti-PD-L1 antibody, atezolizumab, received approval as a second-line treatment option for patients with metastatic NSCLC that provides a significant improvement in OS compared with docetaxel (13.8 versus 9.6 months, HR ¼ 0.73, p ¼ 0.0003). 209 Contrary to the data on nivolumab in patients with nonsquamous NSCLC, 156 the data on atezolizumab demonstrated a significant benefit in patients with tumors that were negative for PD-L1 expression. However, this may be due to the differential sensitivity between the complimentary diagnostic antibody approved for atezolizumab (SP142) and both the companion diagnostic approved for pembrolizumab (22C3) and the complimentary diagnostic approved for nivolumab . 57 Pembrolizumab became the first checkpoint inhibitor to be approved as a first-line treatment option for patients with newly diagnosed stage IV NSCLC, with a superior PFS (10.3 versus 6.0, HR ¼ 0.50, p < 0.001), OS (HR ¼ 0.60, p ¼ 0.005), health-related QOL, and time to deterioration for dyspnea, cough, and chest pain compared with platinum-based chemotherapy in patients with tumors that were EGFR and ALK negative and strongly PD-L1-positive (!50%). 210, 211 A similarly designed study did not show efficacy when nivolumab was compared with chemotherapy; however, in this first-line study, patients with tumors expressing PD-L1 at a lower level of expression (>1% of tumor cells) were enrolled. 212 Firstline avelumab demonstrated efficacy similar to that of currently approved agents, with a 21.2% RR and PFS of 4.2 months (95% CI: 2.8-5.6) in an unselected cohort of patients with NSCLC. 213 Benefit with EGFR/ALK Positivity. The role of immunotherapy, and in particular, immune checkpoint inhibitors, in EGFR mutant and ALK-rearranged NSCLC, has yet to be determined. Retrospective subset analyses from several trials suggest lower rates of response to PD-1 axis inhibitors, without better outcome than standard secondline chemotherapy. [214] [215] [216] That said, some patients benefit from such therapy, as demonstrated in the CheckMate 012 trial. One arm of this trial, 20 patients with EGFR-mutant NSCLC and acquired resistance to EGFR TKI therapy as last therapy were treated with erlotinib and nivolumab; four experienced prolonged tumor regression. 217 Combination therapy was tolerated well; however, increased toxicity, particularly pneumonitis, has been suggested with other TKI and PD-L1 axis inhibitor combinations. 218 Additional arms on the CheckMate 012 trial evaluated combination therapy with nivolumab and ipilimumab; among eight patients with EGFR-mutant NSCLC, four achieved response. 219 Less clinical information exists concerning ALK rearranged NSCLC, although preclinical studies suggest intrinsic PD-L1 upregulation in such tumors, and responsiveness to PD-1 axis inhibition. 220 Currently, whether high tumor PD-L1 expression trumps EGFR or ALK status is uncertain. One retrospective analysis suggested this may not to be the case, with poor outcome with pembrolizumab among 19 patients with high PD-L1-expressing EGFR-mutant NSCLC. 
for patients treated with pembrolizumab plus pemetrexed and carboplatin compared with chemotherapy alone, with a similar incidence of grade 3 or higher adverse events. 222 This led to the U.S. FDA giving accelerated approval for pembrolizumab in combination with pemetrexed and carboplatin for the first-line treatment of metastatic nonsquamous NSCLC irrespective of PD-L1 expression. Multiple trials comparing this approach are ongoing.
The second approach is designing studies that target specific defects in the cancer-immune interaction. Currently mutational burden, 63 tumor-infiltrating lymphocytes, 223 and high PD-L1 224 expression in the tumor microenvironment are associated with sensitivity to immune checkpoint inhibition. Therefore, research efforts should be directed at mapping the state of the cancer immune interaction in a comprehensive manner. 225 A third approach is to create publicly available, open source inventories of large numbers of tissue and blood samples from patients before initiation of immunotherapy and subject such samples to genomics (whole exome sequencing and RNA sequencing), multiplex IHC, flow cytometry, and proteomics analyses, with the results coupled to clinical outcomes. These studies will aid in the characterization of predictors of response and progression. On the basis of these signatures, clinical trials should be performed to test combinations that have been shown to overcome the specific defect in the cancer-immune interaction present in that particular patient population.
Another approach is to treat in earlier disease stages with the aim of increasing cure rates. Early results from melanoma studies suggest that the general immune state of stage III disease patients is better than that of stage IV patients, resulting in a higher RR and more toxicities. 226 Interestingly, pathologic responses have also been observed after neoadjuvant anti-PD-1 in early NSCLC. 227 Earlier-stage patients may require a shorter treatment duration than stage IV patients. Immunotherapy is being actively studied in the neoadjuvant (NCT02259621/ NCT02998528) and the adjuvant (NCT02504372/ NCT02273375) settings in NSCLC.
Finally, as pricing of new immuno-oncology drugs is unlikely to change soon, the aforementioned future directions will certainly lead to a much more costeffective utilization of our resources, as chances for best outcome will be optimal.
SCLC
Section Authors: Corinne Faivre-Finn, MD, PhD, Charles M. Rudin, MD, PhD RT for SCLC. The optimal timing and schedule of thoracic radiation in the management of limited-stage (LS) SCLC continues to provoke debate. Since the publication of Intergroup 0096 in 1999, there has been controversy about the standard chemoradiotherapy regimen in LS disease. 228, 229 At the American Society of Clinical Oncology 2016 annual meeting, the CONVERT trial was presented. 230 This multicenter, international, randomized, phase III trial aimed to establish a standard chemoradiotherapy regimen in LS SCLC. Patients were randomized 1:1 to receive either 45 Gy in 30 twice-daily fractions over 3 weeks or 66 Gy in 33 once-daily fractions over 6.5 weeks starting on day 22 of cycle 1 of chemotherapy, followed by prophylactic cranial irradiation. The study enrolled 547 patients, who were recruited from 73 centers in seven European countries and Canada between 2008 and 2013. Once-daily RT did not result in superior survival or worse toxicity than twice-daily RT (2-year survival of 56% compared with 51% [HR for death in the once-daily group ¼ 1.18, p ¼ 0.14]). The survival for both regimens was higher than previously reported and radiation toxicities were lower than expected, likely because of the use of modern RT techniques. The implications of CONVERT are important. As CONVERT was not an equivalence trial and because the only study to date that has shown superiority for one RT regimen over another in LS SCLC is the Intergroup 0096 trial (which showed no major differences in toxicity), twice-daily RT should continue to be regarded as the standard of care. However, once-daily RT at a dose of 66 Gy in 33 fractions can certainly be considered an alternative regimen if 45 Gy in 30 fractions twice daily cannot be delivered because of patient choice, departmental logistics, or other factors. Given the importance of keeping the overall treatment time short, future studies could investigate dose-escalated twice-daily or hypofractionated RT concurrently with chemotherapy.
For patients with extensive-stage SCLC with residual intrathoracic disease who have responded after induction chemotherapy, addition of thoracic RT reduces the risk for intrathoracic recurrence and improves 2-year survival 231 ; however, the primary end point of 1-year survival was not met. A survey of routine practice presented at the European Society for Radiotherapy and Oncology 2016 conference showed that since publication of the CREST trial there has been a dramatic increase in the use of TRT (from 25% to 81%). 232 Subsequently, a subanalysis of CREST investigating the prognostic importance of the number and sites of metastases was presented at the ASTRO 2016 annual meeting. 233 It suggested that future studies evaluating more intensive thoracic and extrathoracic RT in extensive-stage SCLC focus on patients with fewer than three metastases that are not in the liver or bone.
Advances in Novel Systemic Therapies for SCLC. Several new approaches to systemic treatment of SCLC have recently emerged and have been the subject of recent reviews. 234, 235 These will be touched on here only briefly, but they include combination immunotherapy approaches that have shown substantial efficacy in other diseases, as well as a novel antibody drug conjugate against a cell surface determinant, DLL3, which is relatively unique to SCLC.
In the immunotherapy domain, several of the same PD-1-directed T-cell checkpoint inhibitors already discussed in relation to NSCLC, including both pembrolizumab and nivolumab, have demonstrated initial activity in SCLC. 236, 237 Early data with the combination of nivolumab plus ipilimumab appear particularly promising. In a 216-patient randomized phase II study of nivolumab versus various schedules of nivolumab and ipilimumab, the combination arms demonstrated RRs of 19% to 23% and DCRs of 36% to 42%. 236 The toxicities observed were similar to those reported in other diseases. On the basis of these data, the combination of nivolumab and ipilimumab has been included as a treatment option for recurrent SCLC in the most recent National Comprehensive Cancer Network treatment guidelines for SCLC, and confirmatory trials are ongoing.
DLL3 is an inhibitory Notch ligand that is normally confined to intracellular compartments but is markedly up-regulated and becomes aberrantly cell surfaceexpressed in most SCLC. 238 Rovalpituzumab teserine, or Rova-T, is an antibody drug conjugate directed against DLL3 that demonstrated remarkable preclinical efficacy against SCLC in vivo 238 and promising activity in a firstin-human phase I clinical trial in patients with recurrent metastatic SCLC. 239 Early data suggest that high-level expression of the target, DLL3, may serve as a predictive biomarker for the activity of this agent, as a 38% RR (10 of 26) and DCR of 88% (23 of 26) were observed in two-thirds of patients with DLL3 expressed in more than 50% of the cells. Larger confirmatory trials of Rova-T in SCLC are ongoing.
Mesothelioma
Section Authors: Anne Tsao, MD, Paul Baas, MD, PhD In the past year, the field of mesothelioma treatment has seen a dramatic increase in therapeutic clinical trials.
Several basket trials in immunotherapy with mesothelioma cohorts have reported on the preliminary results of monotherapy PD-1/PD-L1 inhibitors (Table 4) . [240] [241] [242] [243] In general, the reported RRs vary between 9% and 28%, with DCRs of 50% to 77% in unselected patients with mesothelioma. As in NSCLC, checkpoint inhibitors seem to be more active in PD-L1 IHC-positive patients, but the association is not strong. Unfortunately, the cytotoxic T-lymphocyte associated protein inhibitor tremelimumab did not show any benefit over placebo in the DETERMINE trial (NCT01843374). 244 Although there is a preliminary modest signal with PD-1/PD-L1 inhibitors, there is still a critical need to understand the biology and develop novel combination therapies. Combination regimens such as ipilimumab-nivolumab and platinumpemetrexed combinations with PD-1/PD-L1 inhibitors are being investigated in the frontline and salvage settings (Table 5 ). Other approaches encompass neoadjuvant trials with atezolizumab or adjuvant trials with a Wilms' tumor 1 vaccine, galinpepimut-S. 245 In the field of angiogenesis, the French MAPS trial 246 demonstrated a PFS and OS benefit with the addition of bevacizumab to cisplatin-pemetrexed for six cycles of therapy followed by bevacizumab maintenance. On the basis of survival benefit, cisplatin-pemetrexedbevacizumab is now listed in the National Comprehensive Cancer Network guidelines as an approved frontline therapy. On the basis of a significant improvement of PFS, nintedanib combined with cisplatin-pemetrexed has proceeded to a phase III international randomized trial (NCT01907100). In Europe the EORTC is currently studying nintedanib in a phase 2 switch maintenance setting (NCT02863055). The phase II study of cisplatinpemetrexed with or without cediranib (S0905 trial) has completed enrollment and results are anticipated in 2017.
Agents that inhibit metabolism or other novel targets under active investigation include ADI-PEG20 in argininosuccinate synthase 1-deficient mesothelioma (the ATOMIC trial and NCT02709512), mesothelin-targeted agents (SS1P, anetumab ravtasine, and LMB-100), tazemetostat in BRCA1 associated protein 1-deficient However, there is growing recognition that value in cancer care is important to patients and clinicians. Several international bodies, including the American Society of Clinical Oncology and European Society for Medical Oncology, have developed standardized value frameworks to help determine the value of treatments, incorporating the magnitude of clinical benefit, toxicity, and QOL gain without aggregating these measures as a formal cost-effectiveness analysis. [247] [248] [249] For example, the European Society for Medical Oncology Magnitude of Clinical Benefit Scale uses a structured approach to rank treatments by using a four-point scale based on relative and absolute survival gain, toxicity rates, QOL, and use of intermediate end points such as PFS. 247 With a record number of drug approvals, meaningful progress is being made in the areas of targeted and immune therapy in lung cancer. Cost-effectiveness studies suggest that the costs of many new treatments, including multiplex genomic testing, 250 novel targeted kinase inhibitors 251 and checkpoint inhibitors, are above traditional willingness-to-pay thresholds. [252] [253] [254] Each jurisdiction must determine its own willingness to pay for new treatments, which varies across countries and health care systems. Given that severe financial toxicity is recognized as a potential predictor of early mortality in lung and other cancers, 255 implementing strategies to ensure affordable access to treatment has never been more important for patients with lung cancer and their families.
Specific Future Perspectives
Section Authors: Fred R. Hirsch, MD, PhD, Giorgio V. Scagliotti, MD, PhD, David R. Gandara, MD
The past year led to significant progress for new lung cancer therapies based on genomic characterization of patients' tumors and further clinical developments of immunotherapies.
The growing concept of precision medicine addresses this challenge by recognizing the vast, yet fractured state of biomedical data and calls for a patient-centered view in which molecular, clinical, and environmental measurements are stored in large shareable databases. Such efforts have already enabled large-scale knowledge advancement, but they also risk enabling large-scale misuse.
There is still a huge unmet need for identifying new "druggable" molecular targets, particularly in squamous lung cancer and SCLC. Furthermore, much focus has so far been on single-drug development, which has been very encouraging for certain subgroups of patients; in the vast majority of patients, however, combination therapy may be required to convert treatment intent to the "curable" category. Despite the early successes of targeted therapies, it is also becoming evident that primary and acquired resistance are major limitations to long-term survival. Most lung cancers will not be cured by single-agent targeted therapies owing to the inherent genomic complexity, which is now complicated by recognition of heterogeneity in immune biology as well.
Clearly, there is much yet to understand about in vivo tumor biology, and exploring resistance mechanisms is essential to determining which combination of drugs will best treat resistant tumors or prevent the emergence of resistance.
Although pharmaceutical companies are still pursuing many phase II or III combination studies that assess molecular targeted therapies or immunotherapy in combination with chemotherapy, or in combination with each other, study designs remain largely empirical and often without sufficient biological scientific background or rationale for dosing/scheduling for the combinations. Selection of the right therapy for the right patient is crucial, as the new treatments are costly; but most of all, patients with advanced lung cancer have a limited life span and optimizing therapy on an individual basis should be the goal. This is, after all, the definition of precision medicine.
Improved understanding of the cancer immune landscape, including immune evasion strategies, has led to breakthrough therapeutic advances for patients with NSCLC and provides a platform for future therapeutic developments. Better preclinical models need to be developed to study tumor-environment interactions and potential intervention opportunities. Although PD-L1 IHC assessment is used today for PD-L1 and/or PD-1 antibody therapies with some merit (biomarker assays already regulatory approved and used in clinical practice), other biomarkers and synergistic combinatorial biomarker assays need to be explored as predictive "immune signatures."
Several scientific societies and regulatory bodies are concerned about the cost of newer therapies and quantitation of the "value" of each new therapy. Although cost-benefit analysis is increasingly justified, such algorithms are preferably developed by the scientific community rather than dictated by governmental or insurance-based policies.
Lung cancer screening with low-dose CT has demonstrated very encouraging results. However, much research is still needed, particularly as guidelines and new technology develop. Screening opportunities for never-smokers and younger people also need to be explored. It remains crucial to foster future research in lung cancer prevention, early detection, and screening. Although most of the excitement regarding new therapies today focuses on patients with advanced disease, the odds for making lung cancer a curable disease are favored by moving these advances toward early-stage disease. New biomarkers, most likely blood-based assays, to complement the lung cancer screening process are strongly needed to improve the sensitivity and specificity of low-dose CT screening.
Regarding other thoracic malignancies such as mesothelioma and thymoma, lessons learned in lung cancer are now increasingly being applied toward advancing our knowledge about biology, epidemiology, diagnosis, and therapy. Although the future for patients with lung cancer and research appears to be bright, much work remains to be done. 
